AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PATIENTS

Ambisome 与两性霉素 B 治疗艾滋病患者组织胞浆菌病的比较

• 批准号: 6281676
• 负责人: PHILIP C JOHNSON
• 金额: $ 1.36万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281676
• 关键词: AIDS; AIDS therapy; amphotericin B; clinical research; combination chemotherapy; drug screening /evaluation; histoplasmosis; human subject; human therapy evaluation; microorganism disease chemotherapy; opportunistic infections

The aim of this studyis to compare AmBisome as induction therapy for the treatment of moderate to severe disseminated histoplasmosis in patients with AIDS. Patients will be randomized between treatment with IV AmBisome or amphotericin B for two weeks of induction therapy. Patients will then be treated with itraconazole for 10 additional weeks of consolidation therapy to complete a 12 week treatment course. This is a multicenter study of the Mycoses Study Group.

本研究的目的是比较AmBisome作为诱导治疗 治疗中重度播散性组织胞浆菌病 艾滋病 患者将随机接受IV AmBisome治疗 或阿替霉素B进行两周的诱导治疗。 然后患者将 再用伊曲康唑巩固治疗10周 完成为期12周的疗程。 这是一项多中心 真菌病研究小组的研究。